Descrizione del progetto
Intervenire sulla via di segnalazione dei leucotrieni cisteinici per il trattamento di tumori e di malattie dei sistemi visivo e nervoso e dell’apparato cardiovascolare
I leucotrieni cisteinici sono dei noti mediatori lipidici dell’infiammazione. I loro ricettori si trovano nei polmoni, nel colon-retto, nel cuore, nel cervello e nell’occhio e i loro antagonisti vengono impiegati nel trattamento dell’infiammazione. Il progetto CRYSTAL3, finanziato dall‘UE, creerà un team multidisciplinare composto da cinque partner del mondo accademico e da cinque di quello industriale, ponendo l’accento sulla ricerca innovativa nell’ambito della via di segnalazione dei leucotrieni cisteinici in malattie umane che colpiscono i sistemi visivo e nervoso e l’apparato cardiovascolare, nonché nei tumori. L’obiettivo complessivo include la comprensione dei nuovi meccanismi patologici che coinvolgono la via di segnalazione dei leucotrieni cisteinici, scoprendo il loro potenziale terapeutico, oltre a sviluppare prodotti commerciali.
Obiettivo
Cysteinyl leukotrienes (CysLTs) are potent lipid mediators of inflammation. CysLT1 and 2 receptors are widely expressed e.g. lungs, colorectum, heart, brain & eye; and CysLT1 antagonists are prescribed to treat airway inflammation. Excitingly, CysLT signalling was recently discovered to regulate the biology of vascular, neuronal and cancer cells underpinning its untapped therapeutic potential in other diseases. CRYSTAL3 interconnects unique and diverse researchers to create a multidisciplinary team sharing expertise and research capacities. The contribution of CysLT signalling to disease is divulged; its therapeutic potential unlocked and new services & products commercialised. This is delivered by staff exchanges to jointly research Ocular & Central Nervous System (CNS), Cardiovascular system (CV) and Cancer diseases.
The R&I goal of CRYSTAL3 is to reduce human disease burden by enhancing EU capability and knowledge-sharing in research and commercialisation. This is achieved through advanced international co-operation between 5 academic and 5 non-academic partners, in 7 countries. The focus is on innovative research into the CysLT signalling pathway in human diseases related to the Ocular-CNS, & CV systems and Cancer (OCCC).
The 3 overall objectives of CRYSTAL3 are:
A) Combine resources to discover novel pathological mechanisms linking cysteinyl leukotriene signalling to ocular, central nervous system, cardiovascular disease and cancer (OCCC).
B) Unite partner capacities to uncover the therapeutic potential of cysteinyl leukotriene signalling in ocular, central nervous system, cardiovascular disease and cancer (OCCC).
C) Commercialise products and services co-developed within CRYSTAL3
The CRYSTAL3 consortium tackles these challenges by promoting cross-sector, inter-European R&I staff exchanges among participants with expertise in OCCC disease, computational drug discovery, genetic engineering, pre-clinical disease models, marketing and commercialisation.
Campo scientifico
- natural sciencesbiological sciencesneurobiology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesmedical biotechnologygenetic engineering
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesclinical medicineoncology
Parole chiave
Programma(i)
Meccanismo di finanziamento
MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)Coordinatore
4 Dublin
Irlanda